A 62-year-old man with long-standing hypertension and type 2 diabetes has an eGFR of 50 mL/min/1.73 m² and urine albumin-to-creatinine ratio (ACR) of 45 mg/mmol. According to Australian CKD management guidance, which therapy is specifically indicated to slow progression of his kidney disease and reduce cardiovascular risk, in addition to blood pressure control and glycaemic optimisation?